Video

Dr. David Rimm on Immunofluorescence for HER2 Identification

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitativecfor the measurement of HER2 proteins.

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitative immunofluorescence for the measurement of HER2 proteins.

has twice as much dynamic range, and it is more reproducible, says Rimm. The technology makes it easier to match patients with their most effective therapies.

Most immunohistochemistry (IHC) assays, which are traditionally used for the measurement of HER2 proteins, have a 10% to 20% false negative and false positive rate. Quantitative immunofluorescence is more accurate, sensitive,

This practice has not yet caught on with many pathologists yet, but Rimm believes the field will move into that direction once pathologists begin to see its value and it becomes standard practice.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School